GW Pharma (GWPH), Others Dip as DEA Says Marijuana to Remain Schedule I Substance

August 11, 2016 10:07 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

GW Pharma (NASDAQ: GWPH), Cara Therapeutics (NASDAQ: CARA) and Insys Therapeutics (NASDAQ: INSY) dipped lower after the DEA denied requests to loosen the classification of marijuana as a dangerous drug with no medical use.

In comments earlier, Height Securities analyst Stefanie Miller said should marijuana remain a Schedule I substance the news would be negative especially for GW Pharmaceuticals, but also Insys Therapeutics.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment